|
Foresite Capital
Foresite Capital is an American venture capital and growth equity firm headquartered in San Francisco. As of March 2021, the company had raised four funds: Foresite Capital Fund I, II, III, IV and V. History Foresite Capital was founded in 2011 by Jim Tananbaum. Foresite Capital raised its $100 million Fund I in 2013. In 2014, Foresite Capital closed Foresite Capital Fund II, a $300 million fund. Foresite Capital Fund III, a $450 million fund, was closed in July 2015. Foresite Capital Fund IV, a $668 million fund, closed in March 2018. Foresite Capital Fund V, a $969 million fund, was closed in February 2021. Investments Foresite Capital funded 10x Genomics since its Series A round in November 2013 and led its Series B round in January 2015, as well as its Series C round in March 2016. Foresite Capital has invested in companies such as Acceleron Pharma, Aimmune, ALX Oncology, Aerie Pharmaceuticals, Ascendis, Blueprint Medicines, Color Genomics, Cue Health, Cytokinetics, DNAnexus ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Venture Capital
Venture capital (often abbreviated as VC) is a form of private equity financing that is provided by venture capital firms or funds to startups, early-stage, and emerging companies that have been deemed to have high growth potential or which have demonstrated high growth (in terms of number of employees, annual revenue, scale of operations, etc). Venture capital firms or funds invest in these early-stage companies in exchange for equity, or an ownership stake. Venture capitalists take on the risk of financing risky start-ups in the hopes that some of the firms they support will become successful. Because startups face high uncertainty, VC investments have high rates of failure. The start-ups are usually based on an innovative technology or business model and they are usually from high technology industries, such as information technology (IT), clean technology or biotechnology. The typical venture capital investment occurs after an initial "seed funding" round. The first ro ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Immunomedics
Immunomedics was a biotechnology company focused on the development of antibody-drug conjugates for the treatment of cancer. In 2020, the company was acquired by Gilead Sciences. History Immunomedics was founded in July 1982 by David M. Goldenberg. Michael Pehl was named CEO in December 2017 but left due to personal reasons in February 2019. At that time, Dr. Behzad Aghazadeh was named Executive Chairman. In October 2020, Gilead Sciences acquired the company. In March 2022, Gilead announced the closing of the former Immunomedics facility in Morris Plains. Products * Epratuzumab is a humanized anti-CD22 monoclonal antibody in phase III trials for pediatric leukemia. * Sacituzumab govitecan (IMMU-132 / Trodelvy) is an anti-Trop-2-SN-38 antibody-drug conjugate for breast cancer and solid tumors. It was approved in April 2020 by the FDA for the treatment of adult patients with metastatic triple-negative breast cancer Breast cancer is cancer that develops from breast tiss ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Financial Services Companies Established In 2011
Finance is the study and discipline of money, currency and capital assets. It is related to, but not synonymous with economics, the study of production, distribution, and consumption of money, assets, goods and services (the discipline of financial economics bridges the two). Finance activities take place in financial systems at various scopes, thus the field can be roughly divided into personal, corporate, and public finance. In a financial system, assets are bought, sold, or traded as financial instruments, such as currencies, loans, bonds, shares, stocks, options, futures, etc. Assets can also be banked, invested, and insured to maximize value and minimize loss. In practice, risks are always present in any financial action and entities. A broad range of subfields within finance exist due to its wide scope. Asset, money, risk and investment management aim to maximize value and minimize volatility. Financial analysis is viability, stability, and profitability assessment ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Midas List
The ''Forbes'' Midas list is the annual ranking by ''Forbes'' magazine of the most influential and best-performing venture capital investors. Described by Kara Swisher as the "Oscars for venture capitalists in tech," the Midas List uses parameters that include the first-day market capitalization of IPOs and the opinions of a panel of experts. The name alludes to the mythological King Midas Midas (; grc-gre, Μίδας) was the name of a king in Phrygia with whom several myths became associated, as well as two later members of the Phrygian royal house. The most famous King Midas is popularly remembered in Greek mythology for his ..., renowned for his ability to turn anything he touched into gold. ''Forbes'' partnered with venture capital fund TrueBridge Capital Partners to create the list from 2011 to 2016. Midas List Top 30, 2022 According to ''Forbes'', the top 30 venture capitalists in 2022 are as follows: References {{Forbes Magazine Lists Venture capital Priv ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Portola Pharmaceuticals
Portola Pharmaceuticals is an American clinical stage biotechnology company that researches, develops, and commercializes drugs. The company focuses primarily on drugs used in the treatment of thrombosis and hematological malignancies. Founded in 2003 and headquartered in South San Francisco, California, Portola Pharmaceuticals is a member of the NASDAQ Biotechnology Index. In May 2020, Alexion Pharmaceuticals and Portola announced that they had entered into a definitive merger agreement for Alexion to acquire Portola. History The company was founded on September 2, 2003, and named after Gaspar de Portolà, who was the first European to see San Francisco Bay. It completed an IPO on NASDAQ in May 2013. The company developed P2Y12 inhibitor Elinogrel, transferring rights to Novartis in 2009. The rights were returned in 2012 to Portola, which decided not to continue development. Portola Pharmaceuticals has collaboration agreements with SRX Cardio, Dermavant, Millennium Pharm ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Pacific Biosciences
Pacific Biosciences of California, Inc. (aka PacBio) is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio describes its platform as single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides. History The company was founded based on research done at Cornell University that combined semiconductor processing and photonics with biotechnology research. Three graduate students in the lab of Professors Watt W. Webb — Jonas Korlach — and Harold Craighead — Steve Turner and Mathieu Foquet — became the first employees. It began under the name Nanofluidics, Inc. The company raised nearly in six rounds of primarily venture capital financing, making it one of the most capitalized startups in 2010 leading up to their public offering in October of that year. Key investors included Mohr Davidow Ventures, Kleiner, P ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Orexigen Therapeutics
Orexigen Therapeutics is a public American pharmaceutical company focused on development of treatments for obesity. The company is based in La Jolla, California and was established by Eckard Weber in 2002. As a public company, Orexigen is traded on the NASDAQ exchange under the stock symbol OREX. The company has a single product, Contrave, approved for use in the United States in 2014. Contrave was designed not only to curb hunger but also reduce cravings. Observation of the market performance of Qsymia Phentermine/topiramate, sold under the brand name Qsymia, is a combination drug of phentermine and topiramate used to treat obesity. It is used together with dietary changes and exercise. If less than 3% weight loss is seen after 3 months it is r ... and Belviq suggest overall low demand for pharmaceutical obesity therapies, calling into question earnings potential for Orexigen's offering. Orexigen declared bankruptcy in 2018 and was sold to Nalpropion. References Heal ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Natera
Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA (cfDNA) testing technology, with a focus on women’s health, cancer, and organ health. Natera’s proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California and Austin, Texas. History Natera (previously Gene Security Network) was founded by Matthew Rabinowitz and Jonathan Sheena in 2004. Natera launched its first product, the Spectrum preimplantation genetic test, in 2009. In 2010, the company introduced the Anora miscarriage (POC) test. Natera's advanced carrier screening test, Horizon, launched in 2012. The following year, 2013, Natera launched the Panorama non-invasive prenatal test (NIPT). In July ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Juno Therapeutics
Juno Therapeutics Inc is an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. The company raised $300 million through private funding and a further $265 million through their IPO. On January 22, 2018, Juno Therapeutics was acquired by biotechnology company Celgene for $9 billion. In November 2019, Bristol-Myers Squibb (BMS) announced that it has completed its acquisition of Celgene.Bristol ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Intellia Therapeutics
Intellia Therapeutics is a clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. To fully realize the transformative potential of CRISPR-based technologies, Intellia is pursuing two primary approaches. The company’s in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, (with colleagues at University of California, Berkeley) and Virginijus Šikšnys (with colleagues at Vilnius University). The company has entered into a number of different research and development collaborations with l ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Intarcia Therapeutics
Intarcia Therapeutics is an American biopharmaceutical company based in Boston, MA and incorporated under the laws of Delaware. It was founded in 1995 under the name "BioMedicines" and changed to its present name in 2004. In 2013, Intarcia relocated its headquarters to Boston, keeping its manufacturing facility in Hayward, CA. In addition to Boston and Hayward, Intarcia also has a location in Research Triangle Park, Research Triangle Park, North Carolina, where it discovers and develops peptides for its drug delivery system. In 2005, the executive leadership of Intarcia was largely vested in two people, Karling Leung and James Ahlers, President/CEO/Director and Vice President/CFO/Finance & Operations Officer, respectively. By 2012, Kurt Graves had replaced Karling Leung as President and CEO. Kurt Graves has been with Intarcia since August 2010, first serving as Executive Chairman before becoming President and CEO in April 2012. , Intarcia is engaged in development of a "potential ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Growth Capital
Growth capital (also called expansion capital and growth equity) is a type of private equity investment, usually a minority investment, in relatively mature companies that are looking for capital to expand or restructure operations, enter new markets or finance a significant acquisition without a change of control of the business. Companies that seek growth capital will often do so to finance a transformational event in their lifecycle. These companies are likely to be more mature than venture capital funded companies, able to generate revenue and profit but unable to generate sufficient cash to fund major expansions, acquisitions or other investments. Because of this lack of scale, these companies generally can find few alternative conduits to secure capital for growth, so access to growth equity can be critical to pursue necessary facility expansion, sales and marketing initiatives, equipment purchases, and new product development. Growth capital can also be used to effect a ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
